STRS Ohio’s Mineralys Therapeutics MLYS Stock Holding History

STRS Ohio’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324K	Buy	+12,000	New	+$329K	﹤0.01%	1365
2025 Q3	–	Sell	-15,400	Closed	-$208K	–	2252
2025 Q2	$208K	Sell	15,400 -7,200	-32%	-$104K	﹤0.01%	1651
2025 Q1	$359K	Sell	22,600 -4,300	-16%	-$49.5K	﹤0.01%	1334
2024 Q4	$331K	Hold	26,900	–	–	﹤0.01%	1349
2024 Q3	$326K	Buy	26,900 +23,100	+608%	+$280K	﹤0.01%	1420
2024 Q2	$44.5K	Buy	3,800 +2,200	+138%	+$27.7K	﹤0.01%	1811
2024 Q1	$20K	Sell	1,600 -900	-36%	-$11.1K	﹤0.01%	1852
2023 Q4	$21K	Hold	2,500	–	–	﹤0.01%	1846
2023 Q3	$23K	Hold	2,500	–	–	﹤0.01%	1866
2023 Q2	$42K	Hold	2,500	–	–	﹤0.01%	1826
2023 Q1	$39K	Buy	+2,500	New	+$42.1K	﹤0.01%	1811

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

STRS Ohio's MLYS Position: Q2 2026 in Review

STRS Ohio opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 12,000 shares worth $324K. The stake represents ﹤0.01% of the portfolio and ranks #1365 among its holdings. This is a return to the name: STRS Ohio previously reported a position in MLYS as recently as Q2 2025.

STRS Ohio first reported a position in MLYS in Q1 2023 and has held it in 11 quarters since. The position peaked at $359K in Q1 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

STRS Ohio held 12,000 shares of Mineralys Therapeutics worth $324K as of Q2 2026.
Mineralys Therapeutics was a new STRS Ohio position in Q2 2026.
Mineralys Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1365 holding.
STRS Ohio first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 11 quarters since.
STRS Ohio's Mineralys Therapeutics position peaked at $359K in Q1 2025.
226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.